High Cytoplasmic and Membranous Epidermal Growth Factor Receptor (EGFR) Expression as a Risk Factor for High-Grade Ovarian Carcinoma (HGOC)
Open Access
- 30 June 2025
- journal article
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (2) , 1645-1652
Abstract
High-grade ovarian carcinoma (HGOC) is one of the most aggressive grades of ovarian cancer and causes high mortality. The molecular mechanisms underlying the development and progression of high-grade ovarian carcinoma related to high EGFR expression are still not fully understood. This study aimed to evaluate the cytoplasmic and membranous EGFR expression as a risk factor for high-grade ovarian carcinoma. This study employed a case-control design with consecutive sampling among ovarian cancer patients at BaliMed Denpasar Hospital and the Anatomical Pathology Laboratory, Faculty of Medicine and Health Sciences, Warmadewa University. EGFR expression was analyzed immunohistochemically and assessed by H-score. Data were analyzed using the chi-square test and binary logistic regression. P-value ≤ 0.05 was considered significant. This study involved 40 ovarian cancer samples, with the majority (86.7%) aged ≥50 years. The most common histopathological type was endometrioid (45%). As many as 80% of high-grade ovarian cancer (HGOC) cases showed high EGFR expression (>50%), in contrast to low-grade ovarian cancer (LGOC) (40%). High EGFR expression increased the risk of HGOC by 10.5 times (p = 0.001). Multivariate analysis revealed that high EGFR expression was an independent risk factor for HGOC, with an aOR of 41.5 (p-value = 0.008; 95% CI: 2.65–649.14). High EGFR expression was significantly associated with an increased risk of HGOC. Patients with high EGFR expression had a greater risk of HGOC than patients with low to moderate EGFR expression.Keywords
Funding Information
- Universitas Warmadewa (Grant No. 1023/Unwar/FKIK/PD-13/IX/2024)
This publication has 27 references indexed in Scilit:
- Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck TumorsJournal of Cancer Epidemiology, 2020
- PTENMutations and Activation of the PI3K/Akt/mTOR Signaling Pathway in Papillary Tumors of the Pineal RegionJournal of Neuropathology & Experimental Neurology, 2014
- Recent Concepts of Ovarian Carcinogenesis: Type I and Type IIBioMed Research International, 2014
- Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancerCancer Chemotherapy and Pharmacology, 2014
- Targeting EGFR and PI3K pathways in ovarian cancerBritish Journal of Cancer, 2013
- Somatic mutations in aging, cancer and neurodegenerationMechanisms of Ageing and Development, 2012
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancerBritish Journal of Cancer, 2011
- Activated Epidermal Growth Factor Receptor in Ovarian Cancer2009
- The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parametersAPMIS, 2009
- Epithelial growth factor receptor status in primary and recurrent ovarian cancerLaboratory Investigation, 2006